BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 6, 2018--
Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced the hiring of Chad Brines as Vice President, Sales. Mr. Brines
will be responsible for implementing the Company’s commercial strategy
and leading the commercial field organization as the Company prepares
for the launch of DEXTENZA®.
“We are pleased to welcome Chad at such an exciting time for Ocular,”
said Antony Mattessich, President and Chief Executive Officer. “Chad’s
broad background of building and managing sales organizations for both
pharmaceutical and medical device companies is key as we prepare for the
launch of DEXTENZA.”
Mr. Brines brings extensive experience building and leading regional and
national sales organizations in both the pharmaceutical and medical
device industries. Prior to joining Ocular, Mr. Brines most recently
served as a Regional Director for the ophthalmology franchise of
Novartis Pharmaceuticals. Previously, he was a Director of Area Sales at
DJO Global, a medical device company, and a Director of Regional Sales
at Stryker Spine, a Division of Stryker Corporation. Prior to that Mr.
Brines spent over ten years in various sales and marketing roles at
Ethicon Endo-Surgery, Inc., a Johnson & Johnson Company.
About DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg, for
intracanalicular use
DEXTENZA is FDA-approved for the treatment of ocular pain following
ophthalmic surgery. DEXTENZA is a corticosteroid intracanalicular insert
placed in the punctum, a natural opening in the inner portion of the
lower eyelid, and into the canaliculus and is designed to deliver
dexamethasone to the ocular surface for up to 30 days without
preservatives. DEXTENZA resorbs and exits the nasolacrimal system
without the need for removal.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
formulation, development, and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s first commercial drug product, DEXTENZA, is FDA-approved
for the treatment of ocular pain following ophthalmic surgery. OTX-TP
(intracanalicular travoprost insert) is an intracanalicular insert in
Phase 3 clinical development for the reduction of intraocular pressure
in patients with primary open-angle glaucoma and ocular hypertension.
The Company’s earlier stage assets include OTX-TIC, an extended-delivery
intracameral travoprost implant for the reduction of intraocular
pressure in patients with glaucoma and ocular hypertension, as well as
sustained release intravitreal implants for the treatment of retinal
diseases. These intravitreal implants include OTX-TKI, containing a
tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron,
OTX-IVT, an extended-delivery protein-based anti-vascular endothelial
growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
surgery.
Forward Looking Statements
Any statements in this press release about future expectations, plans,
and prospects for the Company, including the commercialization of ReSure
Sealant, DEXTENZA® or any of the Company’s product candidates; the
development and regulatory status of the Company’s product candidates,
such as the Company’s regulatory submissions for and the timing and
conduct of, or implications of results from, clinical trials of DEXTENZA
for the treatment of post-surgical ocular inflammation and the prospects
for approvability of DEXTENZA for post-surgical ocular inflammation or
any other indications, OTX-TP for the treatment of primary open-angle
glaucoma and ocular hypertension, OTX-TIC for the treatment of
primary open-angle glaucoma and ocular hypertension, OTX-TKI for the
treatment of retinal diseases including wet AMD, and OTX-IVT as an
extended-delivery formulation of the VEGF trap aflibercept for the
treatment of retinal diseases including wet AMD; the Company’s
post-approval studies of ReSure® Sealant and the Company’s expectations
regarding its appeal of the warning letter regarding ReSure Sealant; the
ongoing development of the Company’s extended-delivery hydrogel depot
technology; the potential utility of any of the Company’s product
candidates; the potential benefits and future operation of the
collaboration with Regeneron Pharmaceuticals, including any potential
future payments thereunder; the sufficiency of the Company’s cash
resources and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend", "goal," "may", "might,"
"plan," "predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Such forward-looking statements involve
substantial risks and uncertainties that could cause the Company’s
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or implied by
the forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing ReSure Sealant, DEXTENZA or any product candidate that
receives regulatory approval, including the conduct of post-approval
studies, the ability to retain regulatory approval of ReSure Sealant,
DEXTENZA or any product candidate that receives regulatory approval, the
initiation, timing and conduct of clinical trials, availability of data
from clinical trials and expectations for regulatory submissions and
approvals, the Company’s scientific approach and general development
progress, the availability or commercial potential of the Company’s
product candidates, the sufficiency of cash resources, the outcome of
the Company’s ongoing legal proceedings and need for additional
financing or other actions and other factors discussed in the “Risk
Factors” section contained in the Company’s quarterly and annual reports
on file with the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent the
Company’s views as of the date of this release. The Company anticipates
that subsequent events and developments will cause the Company’s views
to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing the Company’s views
as of any date subsequent to the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181206005263/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix
Donald Notman
Chief
Financial Officer
dnotman@ocutx.com
or
Westwicke
Partners
Chris Brinzey
Managing Director
chris.brinzey@westwicke.com
Media
Ocular
Therapeutix
Scott Corning
Senior Vice President, Commercial
scorning@ocutx.com